Dr. Brenda W. Cooper, MD

Dr. Cooper practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Cooper's NPI, 1518986462, was assigned on July 19, 2006. Dr. Cooper graduated from Johns Hopkins University School of Medicine in 1984. Dr. Cooper holds Ohio license 35-059171.

Dr. Cooper's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Cooper's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. Cooper is also affiliated with University Hospitals Parma Medical Center. The medical group on file is University Hospitals Medical Practices.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cooper practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Cooper's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Cooper is licensed in Ohio.

CMS data shows 634 Medicare services from Dr. Cooper across 6 procedure codes in 2024, for 199 Medicare patients. Medicare paid $47,983 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 199 Medicare patients who saw Dr. Cooper in 2024. The largest group is 65 to 74, with 97 patients. 75% of them have high blood pressure, and 74% have high cholesterol. Their average risk score is 2.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cooper's median patient age at 72, with 50% women.

In 2024, Dr. Cooper wrote 1,869 Medicare Part D claims for 212 patients. 59% of them were for generic drugs. CMS names the drug for 1,581 of them, across 33 drugs with 11 or more claims each, at $11,082,744 in total drug cost. In 2023, CMS named 1,679 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Cooper for performance year 2024, reported as part of a group. Dr. Cooper accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 54 papers to Dr. Cooper, published from 2011 to 2025. 2020 was the busiest year, with 6. The most frequent topics are Hematopoietic Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols and Leukemia, Myeloid, Acute. Dr. Cooper has published most often in Bone Marrow Transplant. Dr. Cooper's most frequent co-authors are Marcos Jose Garcia De Lima, MD, Paolo F. Caimi, MD and Leland L. Metheny, MD.

Dmand AI links Dr. Cooper to 10 clinical trials, 4 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Burkitt Lymphoma. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 30 general payments to Dr. Cooper from 18 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 89% of the total. Incyte Corporation paid the most, $303. It also lists 9 research payments totaling $1,742 from 2020 to 2022.

Dr. Cooper graduated from Johns Hopkins University School of Medicine in 1984.